KYTX vs. DNTH, RLAY, IOVA, AMLX, DNA, ARVN, KROS, TNGX, MAZE, and MGTX
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Dianthus Therapeutics (DNTH), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Ginkgo Bioworks (DNA), Arvinas (ARVN), Keros Therapeutics (KROS), Tango Therapeutics (TNGX), Maze Therapeutics (MAZE), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry.
Kyverna Therapeutics vs. Its Competitors
Kyverna Therapeutics (NASDAQ:KYTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.
Dianthus Therapeutics has lower revenue, but higher earnings than Kyverna Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Kyverna Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Kyverna Therapeutics currently has a consensus price target of $18.50, indicating a potential upside of 556.03%. Dianthus Therapeutics has a consensus price target of $53.00, indicating a potential upside of 190.41%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Dianthus Therapeutics.
Kyverna Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,544.23%. Dianthus Therapeutics' return on equity of -29.26% beat Kyverna Therapeutics' return on equity.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Dianthus Therapeutics had 11 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for Dianthus Therapeutics and 1 mentions for Kyverna Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.85 beat Kyverna Therapeutics' score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.
Summary
Dianthus Therapeutics beats Kyverna Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYTX) was last updated on 7/9/2025 by MarketBeat.com Staff
Free KYTX Stock Alerts